References
- Motofei IG, Rowland DL, Baconi DL, et al. Androgenic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018;17(4):407–412.
- Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70:489–498.
- Shanshawal SJ, Dhurat RS. Superiority of dutatseride over finasteride in hair growth and reversal of miniaturization in men with androgenic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venerol Leprol. 2017;83:47–54.
- Tsunemi Y, Irisawa R, Yoshiie H, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenic alopecia. J Dermatol. 2016;43:1051–1058.
- Choi GS, Kim JH, Oh S-Y, et al. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Ann Dermatol. 2016;28(4):444–450.
- Trost L, Saitz TR, Hellstrom WJ. Side effects of 5-alpha reductase inhibitors: a comprehensive review. Sex Med Rev. 2013;1:24–41.
- Amory JK, Wang C, Swerdloff RS, et al. The effect of 5-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–1665.
- Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5α-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179(6):2333–2338.